This stock seems to have entered in radar of Aditya Khema of Incred Healthcare PMS and SOIC.
What prompted me to study this company was hint by Ishmohit.
All ratios have started improving, ranging from Pat(% of sales), EBITA (% of Sales), ROCE, ROE etc
The company seems to be focusing on branded Domestic market and emerging markets specially Myanmar.
It is market leader in immunosuppressant drug (92% market share)
Nephrology, oncology and Urology seem to their focus areas